-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $86

Benzinga·01/08/2026 16:45:33
Listen to the news
Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $80 to $86.